8-K: Adverum's Ixo-vec Shows Promising Results in Wet AMD Phase 2 Trial, Paving Way for Phase 3

Adverum Biotechnologies announced positive preliminary efficacy and safety data from its LUNA Phase 2 trial of Ixo-vec for wet AMD, demonstrating significant reductions in anti-VEGF injections and maintained visual acuity.

Summary

• Adverum Biotechnologies has released preliminary data from its Phase 2 LUNA trial for Ixo-vec, a gene therapy for wet age-related macular degeneration (AMD).
• The trial enrolled 60 patients across two dose cohorts, 2E11 and 6E10 vg/eye, and assessed different corticosteroid prophylaxis regimens.
• Both doses of Ixo-vec showed a significant reduction in the need for anti-VEGF injections, with a 90% reduction at the 6E10 dose and a 94% reduction at the 2E11 dose at 26 weeks.
• Injection-free rates at 26 weeks were 68% for the 6E10 dose and 85% for the 2E11 dose.
• Visual acuity was maintained at both dose levels, with a mean BCVA change of -1.7 letters for the 2E11 dose and +0.5 letters for the 6E10 dose.
• Anatomic endpoints were also maintained, with a mean CST change of -16.4 m for the 2E11 dose and -7.9 m for the 6E10 dose.
• The study identified a favorable prophylactic regimen using Ozurdex and Durezol eye drops, which resulted in over 90% of patients having no or minimal inflammation.
• No Ixo-vec related serious adverse events were reported, and inflammation was responsive to local corticosteroids.
• The company expects to release the 26-week interim analysis in mid-2024 and plans to initiate a Phase 3 trial in the first half of 2025.

Sentiment

Score: 8

Explanation: The document presents very positive preliminary results from the LUNA trial, with significant reductions in treatment burden and a favorable safety profile. The identification of an optimized prophylactic regimen and the plan to move to Phase 3 are also positive indicators. However, the inherent risks associated with clinical trials and regulatory approvals temper the overall sentiment slightly.

Positives

• The LUNA trial showed significant reductions in anti-VEGF injections, with up to 94% reduction at 26 weeks.
• A high percentage of patients remained injection-free, with 85% at the 2E11 dose at 26 weeks.
• Visual acuity and anatomic endpoints were maintained across both dose levels.
• The study identified an optimized prophylactic regimen that significantly reduced inflammation.
• Ixo-vec was generally well-tolerated, with no serious adverse events related to the treatment.
• The results are trending similar to or better than the OPTIC study, which had previously demonstrated long-term efficacy.

Negatives

• Some patients experienced mild to moderate intraocular inflammation, though this was responsive to local corticosteroids.
• There was a slight decrease in mean BCVA of -1.7 letters in the 2E11 dose group, although this was within the confidence interval.
• There was a mean CST change of -7.9 m for the 6E10 dose, which was less than the -16.4 m for the 2E11 dose.

Risks

• The company's novel technology makes it difficult to predict the timing of clinical trials.
• There are regulatory uncertainties associated with the approval process.
• Enrollment uncertainties could impact the timeline of the trials.
• Early clinical trial results may not always be predictive of future clinical trial results.
• There is a potential for future complications or side effects related to Ixo-vec.

Future Outlook

The company anticipates releasing the 26-week interim analysis of the LUNA trial in mid-2024 and plans to initiate a Phase 3 trial in the first half of 2025. They also plan to continue formal and informal regulatory interactions with the FDA and EMA.

Management Comments

• Management believes the preliminary data from the LUNA trial demonstrates the potential of Ixo-vec as a treatment for wet AMD.
• Management is optimistic about the identified prophylactic regimen and its impact on reducing inflammation.
• Management is focused on advancing Ixo-vec through the clinical development process.

Industry Context

This announcement is significant in the context of the broader gene therapy landscape for wet AMD, where there is a high unmet need for treatments that can reduce the burden of frequent injections. The results from the LUNA trial, particularly the reduction in injection frequency and the improved safety profile, position Ixo-vec as a potential competitor to existing anti-VEGF therapies and other emerging gene therapies.

Comparison to Industry Standards

• The reduction in anti-VEGF injections observed in the LUNA trial is comparable to or better than results seen in other gene therapy trials for wet AMD, such as those from companies like REGENXBIO (RGX-314) and 4D Molecular Therapeutics (4D-150).
• The injection-free rates of 68% and 85% at 26 weeks are competitive with other gene therapy approaches that aim to provide long-term efficacy with a single treatment.
• The safety profile, particularly the improved inflammatory response with the optimized prophylactic regimen, is a key differentiator compared to some earlier gene therapy trials that have reported higher rates of inflammation.
• The OPTIC study, which serves as a benchmark for Ixo-vec, demonstrated sustained efficacy outcomes through 3 years, suggesting the potential for long-term benefit with this approach.
• The results are also being compared to standard of care treatments such as aflibercept and ranibizumab, which require frequent injections, highlighting the potential for Ixo-vec to reduce treatment burden.

Stakeholder Impact

• Shareholders are likely to react positively to the promising clinical trial results.
• Patients with wet AMD may benefit from a new treatment option that reduces the need for frequent injections.
• Employees of Adverum may be motivated by the progress of the clinical program.
• The results could impact the competitive landscape for companies developing treatments for wet AMD.

Next Steps

• The company will conduct a 26-week interim analysis of the LUNA trial, expected mid-2024.
• They will continue formal and informal regulatory interactions with the FDA and EMA.
• The company plans to initiate a Phase 3 trial in the first half of 2025.

Key Dates

Keywords

Ixo-vec, wet AMD, gene therapy, anti-VEGF, LUNA trial, clinical trial, ophthalmology, macular degeneration, aflibercept, corticosteroids